A NOVEL HYDRATED FORM OF ERLOTINIB FREE BASE AND A PROCESS FOR PREPARATION OF ERLOTINIB HYDROCHLORIDE POLYMORPH FORM A SUBSTANTIALLY FREE OF POLYMORPH FORM B

摘要

Process for the preparation of erlotinib hydrochloride crystalline polymorph form A substantially free of polymorph form B, erlotinib hydrochloride crystalline polymorph form A and a pharmaceutical composition comprising erlotinib hydrochloride crystalline polymorph form A.